Global Life Science Venture

Global Life Science Ventures (GLSV) was a prominent venture capital firm specializing in the life sciences industry, including biopharmaceuticals, medical devices, and diagnostics. Founded in 1996 and headquartered in Munich, Germany, the firm managed approximately €200 million across two dedicated funds, GLSV I and GLSV II. GLSV focused on early-stage and growth-stage investments, supporting companies originating from academic institutions and the broader industry. Its notable portfolio included successful exits such as Evotec, Exelixis, Valneva, and Pieris Pharmaceuticals. The firm played a vital role in bridging the gap between scientific innovation and commercial success in the European and U.S. markets. GLSV completed its investment cycle and exited its remaining assets in 2015, subsequently entering liquidation.